Multidrug resistance in tumour cells: Characterisation of the multidrug resistant cell line K562-Lucena 1

Anais da Academia Brasileira de Ciencias

Volumn 73, Issue 1, 2001, Pages 56-69

  Rumjanek, Vivian M ^a   Trindade, Gilma S ^a   Wagner Souza, Karen ^a   Meletti De Oliveira, Michele C ^a   Marques Santos, Luis F ^a   Maia, Raquel C ^b   Capella, Márcia A M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Chemosensitisers; Leukaemia; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; VINCRISTINE;

CELL STRAIN K 562; DRUG EFFECT; DRUG RESISTANCE; ERYTHROLEUKEMIA; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PHENOTYPE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; P-GLYCOPROTEIN; PHENOTYPE; VINCRISTINE;

EID: 0039569078     PISSN: 00013765     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0001-37652001000100007     Document Type: Article

References (70)

1. BENCHEKROUN MN, CATROUX P, MONTAUDON D & ROBERT J. 1990. Development of mechanisms of protection against oxidative stress in doxorubicin-resistant rat tumoral cells in culture. Free Radic Res Commun 11: 137-144.
2. BOER R & GEKELER V. 1995. Chemosensitizer in tumor therapy: new compounds promise better efficacy. Drugs Future 20: 499-509.
3. BRINDEIRO PA. 1999. Caracterização de aspectos bioquímicos e moleculares de linhagem eritroleucêmica Lucena 1-K562 envolvidos com o fenótipo MDR. MSc Thesis, Universidade Federal do Rio de Janeiro, Brazil.
4. COLE SPC, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAN AMV & DEELEY RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654.
5. COLE SPC, SPARKS KE, FRASER K, LOE DW, GRANT CE, WILSON GM & DEELEY RG. 1994. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910.
6. COME MG, BETTAIEB A, SKLADANOWSKI A, LARSEN AK & LAURENT G. 1999. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities. Int J Cancer 81: 580-587.
7. DALTON WS. 1997. Mechanisms of drug resistance in hematologic malignancies. Sem Hematol 34: Suppl. 5, 3-8.
8. DELLINGER M, MORENO G, SALET C, TAPIERO H & LAMPIDIS TJ. 1992. Cytotoxic and photodynamic effects of Photofrin on sensitive and multidrug-resistant Friend leukaemia cells. Int J Radiat Biol 62: 735-741.
9. DENIS-GAY M, PETIT J-M, MAZAT J-P & RATINAUD M-H. 1998. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells. Biochem Pharmacol 56: 451-457.
10. EROKHINA M, SHTIL AA, SHUSHANOV SS, SIDOROVA TA & STAVROVSKAYA AA. 1994. Partial restoration of the actin cytoskeleton in transformed Syrian hamster fibroblasts selected for low levels of 'typical' multidrug resistance. FEBS Letters 341: 295-298.
11. FORD JM & HAIT WN. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199.
12. 2+ concentration within the endoplasmic reticulum. Proc Natl Acad Sci USA 97: 5723-5728.
13. GOTTESMAN MM & PASTAN I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
14. GROS P, CROOP J & HOUSMAN D. 1986. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371-380.
15. 2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin. J Biol Chem 269: 7976-7981.
16. HIGGINS CF. 1992. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113.
17. HILL HZ, HILL GJ, CIESZKA K, AZURE M, CHOWDHARY I & SAYRE RM. 1995. A multitherapy resistance factor from melanoma reveals that killing by near UV is different from genotoxic agents. Photochem Photobiol 61: 479-483.
18. HIMES RH, KERSEY RN, HELLER-BETTINGER J & SAMSON FE. 1976. Action of the vinca alkaloids vincristine, vinblastine and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36: 3798-3802.
19. HOBAN PR, ROBSON CN, DAVIES SM, HALL AG, CATTAN AR, HICKSON ID & HARRIS AL. 1992. Reduced topoisomerase II and elevated a class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomicin C. Biochem Pharmacol 43: 685-693.
20. 2+ transport ATPase in the development of thapsigargin resistance by Chinese hamster lung fibroblasts. J Biol Chem 270: 12140-12146.
21. JIA L, LIU K-Z, NEWLAND AC, MANTSCH HH & KELSEY SM. 1999. Pgp-positive leukaemic cells have increased mtDNA but no increased rate of proliferation. Brit J Haematol 107: 861-869.
22. JULIANO RL & LING V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
23. JURANKA PF, ZASTAWNY RL & LING V. 1989. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3: 2583-2592.
24. KOLESNICK RN & KRÖNKE M. 1998. Regulation of ceramide production and apoptosis. Annu Rev Physiol 60: 643-665.
25. KROEMER G, DALLAPORTA B & RESCHE-RIGON M. 1998. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619-642.
26. KÜHL JS, KRAJEWSKI S, DURÁN GE, REED JC & SIKIC BI. 1997. Spontaneous overexpression of the long form of the Bcl-x protein in a highly resistant P388 leukaemia. Br J Cancer 75: 268-274.
27. KUO TH, KIM HR, ZHU L, YU Y, LIN HM & TSANG W. 1998. Modulation of cytoplasmic reticulum calcium pump by Bcl-2. Oncogene 17: 1903-1910.
28. 2+ fluxes. Proc Natl Acad Sci 91: 6569-6573.
29. LEE CH, BRADLEY G, ZHANG JT & LING V. 1993. Differential expression of P-glycoprotein genes in primary rat hepatocyte culture. J Cell Physiol 157: 392-402.
30. LEE W-P. 1995. Purification and characterization of tubulin from parental and vincristine-resistant HOB1 lymphoma cells. Arch Biochem Biophys 319: 498-503.
31. LENEHAN PF, GUTIERREZ PL, WAGNER JL, MILAK N, FISHER GR & ROSS DD. 1995. Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to the resistance to daunorubicin manifested by these cells. Cancer Chemother Pharmacol 35: 377-386.
32. LEVENSON R, MACARA IG, SMITH RL, CANTLEY L & HOUSMAN D. 1982. Role of mitochondrial membrane potential in the regulation of murine erythroleukemia cell differentiation. Cell 28: 855-863.
33. LIST AF, SPIER C, GREER J, WOFF S, HUTTER J, DORR R, SALMON S, FUTSCHER R, BAIER M & DALTON W. 1993. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660.
34. LUCCI A, GIULIANO AE, HAN TY, DINUR T, LIU YY, SENCHENKOV A & CABOT MC. 1999. Ceramide toxicity and metabolism differ in wild-type and multidrug-resislant cancer cells. Int J Oncol 15: 535-540.
35. MAIA RC, SILVA EAC, HARAB RC, LUCENA M, PIRES V & RUMJANEK VM. 1996a. Sensitivity of vincristine-sensitive K562 and vincristine resistant Lucena-1 cells to anthracyclines and reversal of multidrug resistance. Braz J Med Biol Res 29: 467-472.
36. MAIA RC, WAGNER K, CABRAL RH & RUMJANEK VM. 1996b. Heparin reverses rhodamine 123 extrusion by multidrug resistant cells. Cancer Lett 106: 101-108.
37. MARKS DC, DAVEY MW, DAVEY RA & KIDMAN AD. 1995. Expression of multidrug resistance in response to differentiation in the K562 leukaemia cell line. Biochem Pharmacol 50: 475-480.
38. MARQUES-SILVA VM. 1996. Efeito de moduladores da diferenciação celular no processo de resistência a múltiplas drogas. PhD Thesis, Universidade Federal Fluminense, Brazil.
39. MARQUES-SILVA VM, DE SOUZA MHO, TEIXEIRA MCL, ARCURI RA & RUMJANEK VM. 1990. Myeloid leukemia differentiation by phorbol ester and retinoic acid: a practical approach. J Clin Lab Anal 4: 342-349.
40. MATSUMOTO Y, TAKANO H & FOJO T. 1997. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res 57: 5086-5092.
41. MAZZANTI R, FANTAPPIÈ O, FABRIZIO P & RELLI P. 1995. Susceptibility to lipid peroxidation of human hepatocellular carcinoma cell lines with different levels of multiple drug-resistant phenotype. Lab Inv 73: 419-423.
42. MERRILL AH JR & JONES DD. 1990. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta 1044: 1-12.
43. MILZANI A, DALLEDONNE I & COLOMBO R. 1997. Prolonged oxidative stress on actin. Arch Biochem Biophys 2: 267-274.
44. MIZUNO K, FURUHASHI Y, MISAWA T, IWATA M, KAWAI M, KIKKAWA F, KANO T & TOMODA Y. 1992. Modulation of multidrug resistance by immunosupressive agents: cyclosporin analogues, FK506 and Mizoribine. Anticancer Res 12: 21-25.
45. MODRAK DE, DRAPER MP & LEVY SB. 1997. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines. Biochem Pharmacol 54: 1297-1306.
46. MULLER M, MEIJER C, ZAMAN GJR, BORST P, SCHEPER RJ, MULDER NH, DE VRIES EGE & JANSEN PLM. 1994. Overexpression of the gene encoding the multidrug resistant-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci 91: 13033-13037.
47. NEEFJES JJ, MOMBURG F & HAMMERLING GJ. 1993. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261: 769-771.
48. NEYFAKH AA. 1988. Use of fluorescent dyes as molecular probes for the studies of multidrug resistance. Exp Cell Res 174: 168-176.
49. OKABE-KADO J, HAYASHI M, HONMA Y & HOZUMI M. 1986. Enhancement by hemin of the sensitivity of K562 human leukemic cells to 1-β-arabinofuranosylcytosine. Cancer Res 46: 1239-1243.
50. OKABE-KADO J, HAYASHI M, HONMA Y, HOZUMI M & TSURUO T. 1991. Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells. Cancer Res 51: 2582-2586.
51. ORIND M, WAGNER-SOUZA K, MAIA RC & RUMJANEK VM. 1997. Modulation of P-glycoprotein on tumour cells. In: Sotelo JR & Benech JC (Ed.): Calcium and cellular metabolism: transport and regulation. New York: Plenum Press, p. 117-124.
52. PATTERSON KK, BECKMAN BS, KLOTZ DM, MALLIA CM & JETER JR. 1996. Dexniguldipine hydrochloride, a protein-kinase-C-specinc inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells. J Cancer Res Clin Oncol 122: 465-475.
53. PÉTRIZ J & GARCIA-LÓPEZ J. 1997. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11: 1124-1130.
54. PUTNEY JW. 1990. Capacitative calcium entry revisited. Cell Calcium 11: 611-624.
55. RAFFERTY NS, RAFFERTY KA & ZIGMAN S. 1997. Comparative response to UV irradiation of cytoskeletal elements in rabbit and skate lens epithelial cells. Curr Eye Res 6: 310-319.
56. 2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells. Nucleic Acids Res 26: 4529-4537.
57. RUMJANEK VM, LUCENA M, CAMPOS MM, MARQUES-SILVA VM & MAIA RC. 1994. Multidrug resistance in leukemias: the problem and some approaches to its circumvention. Ciencia Cult 46: 63-69.
58. 2+ transport ATPases by thapsigargin. J Biol Chem 267: 12606-12613.
59. SCHEFFER GL, WIJNGAARD PLJ, FLENS MJ, IZQUIERDO MA, SLOVAK ML, PINEDO HM & SCHEPER RJ. 1995. The drug resistance-related protein LRP is the major vault protein. Nat Med 1: 578-582.
60. SEIDEL A, HASMANN M, LOSER R, BUNGE A, SCHAEFER B, HERZIG I, STEIDTMANN K & DIETEL M. 1995. Intracellular localisation, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells. Virchows Arch 426: 249-256.
61. TANAKA K, HIRAI M, TANIGAWARA Y, YASUHARA M, HORI R, UEDA K & INUI K. 1996. Effect of Cyclosporin A analogues and FK506 on transcellular transport of Daunorubicin and Vimblastine via P-glycoprotein. Pharmaceutical Res 13: 1073-1077.
62. 2+ ATPase. Proc Natl Acad Sci USA 87: 2466-2470.
63. th International Cancer Congress. Bologna. Monduzzi Editore, p. 179-182.
64. TRINDADE GS, CAPELLA MAM, CAPELLA LS, AFFONSO-MITTIDIERI OR & RUMJANEK VM. 1999. Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Photochem Photobiol 69: 694-699.
65. TRINDADE GS, FARIAS SL, RUMJANEK VM & CAPELLA MAM. 2000. Methylene blue reverts multidrug resistance sensitivity of multidrug resistance cells to this dye and its photodynamic action. Cancer Lett 151: 161-167.
66. TSURUO T, IIDA H, TSUKAGOSHI S & SAKURAI Y. 1981. Overcoming of vincristine resistance in P388 leukemia "in vivo" and "in vitro" through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972.
67. TSURUO T, IIDA H, OHKOCHI E, TSUKAGOSHI S & SAKURAI Y. 1983. Establishment and properties of a vincristine-resistant human myelogenous leukemia K562. Jpn J Cancer 74: 751-758.
68. UCHIDA N, COMBS J, CHEN S, ZANJANI E, HOFFMAN R & TSUKAMOTO A. 1996. Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood 88: 1297-1305.
69. YANOVICH S, HALL RE & GEWIRTZ DA. 1989. Characterization of a K562 multidrug-resistant cell line. Cancer Res 49: 4499-4501.
70. ZAMZAMI N, MARCHETTI P, CASTEDO M, ZANIN C, VAYSSIERE JL, PETIT PX & KROEMER G. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 181: 1661-1672.